CBD:THC Extract Ratio for Neuropathic Pain Relief

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for neuropathic pain, particularly those involving opioids, are often ineffective and can have significant side effects, and there is a need for more efficient and sustainable methods to manage chronic neuropathic pain that affects a substantial portion of the population.

Innovation Solution

A cannabis-based medicinal extract comprising a ratio of cannabidiol (CBD) to tetrahydrocannabinol (THC) between 18:1 and 30:1, derived from plant extracts, is used to treat peripheral neuropathic pain, potentially combined with other medicinal substances and administered in titratable dosage forms to optimize pain relief.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If opioids are used to treat neuropathic pain, then pain relief may be achieved, but the treatment is often ineffective and produces significant side effects

Engineering Contradiction:

Improveeffectiveness of pain reliefVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies parameter changes by optimizing the ratio of CBD to THC within the range of 18:1 to 30:1. This specific ratio parameter modification enables effective neuropathic pain relief while minimizing the harmful side effects associated with conventional opioid treatments, thus resolving the contradiction between effectiveness and side effects

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The patent employs composite materials by combining CBD and THC in a specific ratio to create a synergistic formulation. This composite approach leverages the complementary properties of both cannabinoids, achieving reliable pain relief without the significant side effects of opioids, thereby resolving the technical contradiction

Inventive Principle:

Principle #40Composite materials

2Device complexity

If pure CBD or THC is used alone, then treatment is simpler, but efficacy in relieving neuropathic pain is reduced

Engineering Contradiction:

Improvetreatment formulation complexityVSAvoidpain relief efficacy

Core Design Contradiction:

Device complexityVSReliability

Solution Approach 1:

The patent merges CBD and THC into a single formulation with a optimized ratio of 18:1 to 30:1. This combination approach enhances pain relief efficacy compared to using either cannabinoid alone, while maintaining a relatively simple administration protocol, thus resolving the contradiction between formulation complexity and treatment efficacy

Inventive Principle:

Principle #5Merging (Combining)

3Reliability

If current pharmaceutical treatments are used, then some pain relief is achieved, but the treatments are often ineffective for chronic neuropathic pain

Engineering Contradiction:

Improveeffectiveness of pain reliefVSAvoidsustainability of pain relief

Core Design Contradiction:

ReliabilityVSDuration of action of moving object

Solution Approach 1:

The patent applies parameter changes by optimizing the CBD:THC ratio to between 18:1 and 30:1, which provides both effective acute pain relief and sustained long-term management of chronic neuropathic pain, resolving the contradiction between immediate effectiveness and durability of treatment

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentEP2037902B1Cannabinoids for use in the treatment of neuropathic pain

Publication Date: 2013.07.03 GW PHARMA LIMITED

Figure 1
Figure 2
Figure 3

AI summary

The present invention relates to the use of cannabidiol (CBD) type compounds or derivative thereof and tetrahydrocannabinol (THC) type compounds or derivative thereof in the manufacture of a medicament for the treatment of neuropathic pain. Preferably the ratio of the CBD type compounds or derivative thereof and THC type compounds or derivative thereof is between 18:1 and 30:1. More preferably the CBD type compounds or derivative thereof and THC type compounds or derivative thereof are in the form of plant extracts.